A Phase 1 Study in up to 2 Parts, to Assess the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of AMT-126 in the Fasted State (in Part 1) and to Evaluate the In Vivo Performance of an AMT-126 Oral Tablet Through Pharmacoscintigraphic Assessment in the Fed and Fasted State (in Optional Part 2) in Healthy Male and Female Subjects
Latest Information Update: 01 Aug 2022
At a glance
- Drugs AMT 126 Cyclo Therapeutics (Primary)
- Indications Gastrointestinal disorders
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Applied Molecular Transport
- 24 Feb 2022 According to an Applied Molecular Transport media release, program update from oral AMT-126 is expected in H1 2022.
- 10 Aug 2021 According to an Applied Molecular Transport media release, topline data readout expected in 2022.
- 03 Mar 2021 New trial record